White-label 3-site STI test kits: a planning guide for telehealth and employer programs

A urine-only STI kit is easy to build, easy to ship and easy for patients to use. For a lot of programs it's also incomplete. Gonorrhea and chlamydia can live in the throat and rectum without symptoms, and a urine sample won't find them there. That's why more telehealth platforms and employer health programs are asking for 3-site kits: one box with a throat swab, a rectal swab and a urine specimen collection cup or genital swab.

This guide walks through what CDC guidance says about testing by exposure site, what goes into a well-designed 3-site kit, and the operational questions to settle with a lab partner before you put your brand on the box.

What "3-site" testing means

A 3-site STI test checks for chlamydia and gonorrhea at each place a person may have been exposed:

• Throat (pharyngeal): a self-collected oropharyngeal swab

• Rectum: a self-collected rectal swab

• Genital: first-catch urine, or a vaginal swab for people with a vagina

Each specimen is tested with a nucleic acid amplification test (NAAT). In 2019 the FDA cleared the first NAATs for throat and rectal specimens; before that, cleared chlamydia and gonorrhea tests covered only urine, vaginal and endocervical samples.

Why urine-only kits miss infections

CDC's 2021 STI Treatment Guidelines, which remain its current clinical guidance, are direct about this for men who have sex with men (MSM). The guidelines call rectal and pharyngeal testing by NAAT "an important sexual health consideration" and note that rectal and throat infections can be found even when patients don't report the related exposure.

For sexually active MSM, CDC's screening recommendations say to test for gonorrhea at least annually at each site of contact (urethra, rectum and pharynx), and every 3 to 6 months for people at increased risk, including many PrEP users. The MSM section of the guidelines adds a few details that matter for kit design:

• Rectal testing for both gonorrhea and chlamydia is recommended after receptive anal sex in the past year.

• Pharyngeal testing is recommended for gonorrhea. Routine pharyngeal chlamydia screening is not recommended, though a positive result found while testing for gonorrhea should be treated.

• Provider-collected or self-collected rectal and throat specimens are both acceptable.

For women, CDC recommends annual chlamydia and gonorrhea screening for sexually active women under 25 and for those 25 and older at increased risk. Rectal and pharyngeal testing can be considered based on reported sexual behaviors, through shared decision-making between the patient and clinician. Screening for transgender and gender-diverse people should follow anatomy and reported exposures.

The practical takeaway: a single kit design rarely fits everyone. The best programs let the ordering clinician pick the sites that match a patient's history.

Self-collection is well supported

The main worry teams raise about at-home swabs is whether patients can collect them well. CDC's chlamydia guidance reports that patient-collected vaginal swabs perform as well as clinician-collected ones by NAAT, that self-collected rectal swabs are comparable to clinician-collected rectal swabs, and that both approaches are highly acceptable to patients.

The regulatory picture has moved too. In November 2023 the FDA authorized the first chlamydia and gonorrhea test with at-home sample collection, and in March 2025 it authorized the first fully at-home test for chlamydia, gonorrhea and trichomoniasis. Neither changes how a lab-processed kit works, but both show how quickly home collection has become a normal part of STI care. For any kit you launch, ask your lab which collection devices and specimen types it has validated for home use.

What goes into a 3-site kit

A clear kit gets better returns. Most well-run kits include:

• One labeled collection device per site, so specimens can't be mixed up

• A simple instruction card with step-by-step pictures for each swab

• A requisition or barcode that ties every tube to the right patient and site

• Leak-proof biohazard bags and absorbent material

• Prepaid return packaging that meets shipping rules for exempt specimens

• Optional add-ons, such as a fingerstick blood sample for syphilis or hepatitis C, when the clinician orders them

Small details make a big difference. Color-coding tubes by site, keeping instructions to one page, and adding a short how-to video link all tend to cut down on rejected or mislabeled samples.

Why white-label matters

For a telehealth brand, the kit is often the only physical thing a patient holds. A white-label test kit puts your name on the box, the insert and the results experience, while a licensed lab does the testing behind the scenes. That keeps the patient relationship with you and avoids handing them off to another brand halfway through care.

Discretion counts even more for sexual health. Plain outer packaging, neutral return labels and a results portal under your brand all help patients feel comfortable ordering and returning a kit.

Telehealth vs. employer programs

The kit can be identical. The program around it usually isn't.

Telehealth platforms

• Clinicians order by site, based on a sexual history taken during the visit.

• Kits often ship on a schedule, for example every 3 months for PrEP patients, timed so results arrive before a refill.

• Results should flow straight into the clinical record through an API or EMR integration, so positives trigger treatment and partner notification quickly. If you're building this, a lab partner for telehealth should be able to show exactly how orders and results move.

Employer health programs

• Testing is offered as a voluntary, confidential benefit, often through a telehealth or benefits vendor that provides the ordering clinician.

• Individual results should go to the employee and their clinician, never to the employer. Employers typically see only de-identified, aggregate use data, if anything.

• Clear communication about privacy and what happens after a positive result drives participation more than any other factor.

Questions to ask a lab partner

Before you commit, get clear answers to these:

1. Which specimen types and collection devices are validated for self-collection at home, and for which sites?

2. Can clinicians order sites individually, or is the panel fixed?

3. How long are specimens stable in transit, and what happens to a sample that arrives too late?

4. How are mislabeled or leaking samples handled, and how is the patient told?

5. How do orders and results move: API, EMR integration or a portal?

6. Which certifications and state licenses does the lab hold for the states you serve?

7. Who builds, stores and ships the kits, and how is inventory tracked?

Bringing it together

A 3-site kit is one of the simplest ways to close a known gap in STI screening, especially for MSM and PrEP programs. The testing science is settled. What sets programs apart is the operation: kits patients can actually complete, ordering that follows each patient's exposure history, and results that reach clinicians fast.

IHDLab is a CLIA-certified lab (CLIA 05D2040304) licensed in California, New York and Maryland that works only with business partners, including telehealth platforms that run PrEP and STI testing programs. If you're mapping out a 3-site kit, we're happy to compare notes.

This article is for educational purposes and isn't medical advice. Screening decisions belong to the ordering clinician and current CDC guidance.